CA2584225A1

CA2584225A1 - Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists

Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists Download PDF

Info

Publication number: CA2584225A1
Authority: CA; Canada
Prior art keywords: niacin; analog; tetrazol; pyrazole; benzyl
Prior art date: 2004-11-05
Legal status : Abandoned

Application number

CA002584225A

Other languages

English (en)

French (fr)

Inventor

Dominic P. Behan

Daniel T. Connolly

Jeremy Richman

Current Assignee

Arena Pharmaceuticals Inc

Original Assignee

Individual

Priority date

2004-11-05

Filing date

2005-11-01

Publication date

2006-05-18

2005-11-01 Application filed by Individual filed Critical Individual

2006-05-18 Publication of CA2584225A1 publication Critical patent/CA2584225A1/en

Status Abandoned legal-status Critical Current

Links

108700010041 Nicotinic acid receptor Proteins 0.000 title claims abstract description 174
239000004031 partial agonist Substances 0.000 title claims abstract description 135
238000011010 flushing procedure Methods 0.000 title claims abstract description 124
150000002632 lipids Chemical class 0.000 title claims abstract description 120
239000000203 mixture Substances 0.000 title claims description 95
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 306
239000011664 nicotinic acid Substances 0.000 claims abstract description 300
235000001968 nicotinic acid Nutrition 0.000 claims abstract description 299
229960003512 nicotinic acid Drugs 0.000 claims abstract description 299
150000006636 nicotinic acid Chemical class 0.000 claims abstract description 239
238000000034 method Methods 0.000 claims abstract description 92
150000001875 compounds Chemical class 0.000 claims description 169
150000003839 salts Chemical class 0.000 claims description 48
239000003623 enhancer Substances 0.000 claims description 38
239000003112 inhibitor Substances 0.000 claims description 36
238000006243 chemical reaction Methods 0.000 claims description 28
125000003226 pyrazolyl group Chemical group 0.000 claims description 28
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 27
230000002829 reductive effect Effects 0.000 claims description 27
230000015572 biosynthetic process Effects 0.000 claims description 26
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 25
125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims description 25
LTQYSJKGRPGMPO-UHFFFAOYSA-N 3-(2h-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole Chemical compound C1=2CCCC=2NN=C1C1=NN=NN1 LTQYSJKGRPGMPO-UHFFFAOYSA-N 0.000 claims description 23
CXBPIKBDSFXEMF-UHFFFAOYSA-N 3-(2h-tetrazol-5-yl)-4,6-dihydro-1h-thieno[3,4-c]pyrazole Chemical compound C1SCC=2C1=NNC=2C1=NN=NN1 CXBPIKBDSFXEMF-UHFFFAOYSA-N 0.000 claims description 23
125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 23
VYGUDGUPIFVQNE-UHFFFAOYSA-N 5-[(3-bromophenyl)methyl]-1h-pyrazole-3-carboxylic acid Chemical compound N1N=C(C(=O)O)C=C1CC1=CC=CC(Br)=C1 VYGUDGUPIFVQNE-UHFFFAOYSA-N 0.000 claims description 23
UYMDSFKYOCEPFN-UHFFFAOYSA-N 5-[(3-chlorophenyl)methyl]-1h-pyrazole-3-carboxylic acid Chemical compound N1N=C(C(=O)O)C=C1CC1=CC=CC(Cl)=C1 UYMDSFKYOCEPFN-UHFFFAOYSA-N 0.000 claims description 23
DWGHGHIWIZJJKX-UHFFFAOYSA-N 5-[(3-fluorophenyl)methyl]-1h-pyrazole-3-carboxylic acid Chemical compound N1C(C(=O)O)=CC(CC=2C=C(F)C=CC=2)=N1 DWGHGHIWIZJJKX-UHFFFAOYSA-N 0.000 claims description 23
QFLSWJUOMICBKB-UHFFFAOYSA-N 6-methyl-3-(2h-tetrazol-5-yl)-4,6-dihydro-1h-furo[3,4-c]pyrazole Chemical compound CC1OCC=2C1=NNC=2C1=NN=NN1 QFLSWJUOMICBKB-UHFFFAOYSA-N 0.000 claims description 23
238000003786 synthesis reaction Methods 0.000 claims description 23
PWTAIWVYJBIWDV-UHFFFAOYSA-N 3-(2h-tetrazol-5-yl)-1,4-dihydrocyclopenta[c]pyrazole Chemical compound C1=2CC=CC=2NN=C1C=1N=NNN=1 PWTAIWVYJBIWDV-UHFFFAOYSA-N 0.000 claims description 22
HEPHDXKADNILNS-UHFFFAOYSA-N 5-(5-propan-2-yl-1h-pyrazol-3-yl)-2h-tetrazole Chemical compound N1C(C(C)C)=CC(C=2NN=NN=2)=N1 HEPHDXKADNILNS-UHFFFAOYSA-N 0.000 claims description 22
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 22
SWSJDJYGSQGAFF-UHFFFAOYSA-N 3-(2h-tetrazol-5-yl)-1,6-dihydrocyclopenta[c]pyrazole Chemical compound C1C=CC2=C1NN=C2C1=NN=NN1 SWSJDJYGSQGAFF-UHFFFAOYSA-N 0.000 claims description 21
FTXOPGWMJLXSRU-UHFFFAOYSA-N 3-(2h-tetrazol-5-yl)-4,6-dihydro-1h-furo[3,4-c]pyrazole Chemical compound C1OCC=2C1=NNC=2C1=NN=NN1 FTXOPGWMJLXSRU-UHFFFAOYSA-N 0.000 claims description 21
125000006279 3-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Br)=C1[H])C([H])([H])* 0.000 claims description 21
125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims description 21
125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims description 21
SECXDPVXDUGTCU-UHFFFAOYSA-N 5-ethyl-3-(2h-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole Chemical compound C=12CC(CC)CC2=NNC=1C1=NN=NN1 SECXDPVXDUGTCU-UHFFFAOYSA-N 0.000 claims description 21
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 21
230000003914 insulin secretion Effects 0.000 claims description 20
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 18
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 18
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 18
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 18
229940125753 fibrate Drugs 0.000 claims description 18
229940031439 squalene Drugs 0.000 claims description 18
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 18
229940123208 Biguanide Drugs 0.000 claims description 17
229940123464 Thiazolidinedione Drugs 0.000 claims description 17
239000003288 aldose reductase inhibitor Substances 0.000 claims description 17
239000003795 chemical substances by application Substances 0.000 claims description 17
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 16
230000015556 catabolic process Effects 0.000 claims description 16
239000005541 ACE inhibitor Substances 0.000 claims description 15
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 15
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 14
229940118148 Aldose reductase inhibitor Drugs 0.000 claims description 14
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 14
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 13
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 13
210000004027 cell Anatomy 0.000 description 69
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 63
208000035475 disorder Diseases 0.000 description 60
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 59
238000003556 assay Methods 0.000 description 58
239000000243 solution Substances 0.000 description 55
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
102000005962 receptors Human genes 0.000 description 44
108020003175 receptors Proteins 0.000 description 44
238000002360 preparation method Methods 0.000 description 41
229910001868 water Inorganic materials 0.000 description 41
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 38
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 38
229940095074 cyclic amp Drugs 0.000 description 38
239000007787 solid Substances 0.000 description 33
201000001320 Atherosclerosis Diseases 0.000 description 32
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
238000009739 binding Methods 0.000 description 30
241000699670 Mus sp. Species 0.000 description 29
230000027455 binding Effects 0.000 description 29
239000003814 drug Substances 0.000 description 28
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
108010023302 HDL Cholesterol Proteins 0.000 description 26
238000009472 formulation Methods 0.000 description 26
229910052757 nitrogen Inorganic materials 0.000 description 26
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 25
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 25
108010007622 LDL Lipoproteins Proteins 0.000 description 25
102000007330 LDL Lipoproteins Human genes 0.000 description 25
235000012000 cholesterol Nutrition 0.000 description 25
239000000126 substance Substances 0.000 description 25
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
235000019439 ethyl acetate Nutrition 0.000 description 24
-1 6-OH-nicotinamide Chemical compound 0.000 description 23
239000000872 buffer Substances 0.000 description 23
230000000694 effects Effects 0.000 description 23
239000000463 material Substances 0.000 description 23
239000012528 membrane Substances 0.000 description 23
210000002966 serum Anatomy 0.000 description 23
229940079593 drug Drugs 0.000 description 22
238000011282 treatment Methods 0.000 description 22
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
210000004369 blood Anatomy 0.000 description 20
239000008280 blood Substances 0.000 description 20
239000003826 tablet Substances 0.000 description 20
239000000556 agonist Substances 0.000 description 18
239000002775 capsule Substances 0.000 description 18
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 16
238000005481 NMR spectroscopy Methods 0.000 description 16
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
235000021588 free fatty acids Nutrition 0.000 description 16
230000003834 intracellular effect Effects 0.000 description 16
239000008194 pharmaceutical composition Substances 0.000 description 15
230000009467 reduction Effects 0.000 description 15
239000013598 vector Substances 0.000 description 15
230000004044 response Effects 0.000 description 14
VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 14
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 13
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 13
108010010234 HDL Lipoproteins Proteins 0.000 description 13
102000015779 HDL Lipoproteins Human genes 0.000 description 13
108010028554 LDL Cholesterol Proteins 0.000 description 13
239000004480 active ingredient Substances 0.000 description 13
238000011534 incubation Methods 0.000 description 13
239000000843 powder Substances 0.000 description 13
238000013268 sustained release Methods 0.000 description 13
239000012730 sustained-release form Substances 0.000 description 13
238000008214 LDL Cholesterol Methods 0.000 description 12
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
230000004913 activation Effects 0.000 description 12
239000012148 binding buffer Substances 0.000 description 12
230000008859 change Effects 0.000 description 12
108091006027 G proteins Proteins 0.000 description 11
102000030782 GTP binding Human genes 0.000 description 11
108091000058 GTP-Binding Proteins 0.000 description 11
125000000217 alkyl group Chemical group 0.000 description 11
239000012131 assay buffer Substances 0.000 description 11
238000004128 high performance liquid chromatography Methods 0.000 description 11
BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 11
BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
239000000725 suspension Substances 0.000 description 11
239000007995 HEPES buffer Substances 0.000 description 10
108010052285 Membrane Proteins Proteins 0.000 description 10
239000003446 ligand Substances 0.000 description 10
239000007788 liquid Substances 0.000 description 10
239000008188 pellet Substances 0.000 description 10
229920001184 polypeptide Polymers 0.000 description 10
102000004196 processed proteins & peptides Human genes 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 10
239000002904 solvent Substances 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
241000700159 Rattus Species 0.000 description 9
150000001413 amino acids Chemical class 0.000 description 9
125000004432 carbon atom Chemical group C* 0.000 description 9
238000001514 detection method Methods 0.000 description 9
239000000047 product Substances 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
MAKIKJKHLUWTOW-UHFFFAOYSA-N 1-benzyl-3-(2h-tetrazol-5-yl)-5,6-dihydro-4h-cyclopenta[c]pyrazole Chemical compound N1=C(C2=NNN=N2)C=2CCCC=2N1CC1=CC=CC=C1 MAKIKJKHLUWTOW-UHFFFAOYSA-N 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
229940024606 amino acid Drugs 0.000 description 8
235000001014 amino acid Nutrition 0.000 description 8
238000013459 approach Methods 0.000 description 8
235000005911 diet Nutrition 0.000 description 8
230000037213 diet Effects 0.000 description 8
239000002552 dosage form Substances 0.000 description 8
238000013265 extended release Methods 0.000 description 8
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
235000017557 sodium bicarbonate Nutrition 0.000 description 8
229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
238000001890 transfection Methods 0.000 description 8
RUYWILNRQBUQRK-UHFFFAOYSA-N 1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide Chemical compound C1CCC2=C1NN=C2C(=O)N RUYWILNRQBUQRK-UHFFFAOYSA-N 0.000 description 7
VQZBZGSSNLQSCA-UHFFFAOYSA-N 1-benzyl-5,6-dihydro-4h-cyclopenta[c]pyrazole-3-carboxamide Chemical compound C1=2CCCC=2C(C(=O)N)=NN1CC1=CC=CC=C1 VQZBZGSSNLQSCA-UHFFFAOYSA-N 0.000 description 7
108020004414 DNA Proteins 0.000 description 7
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
229940125904 compound 1 Drugs 0.000 description 7
239000011888 foil Substances 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
239000000700 radioactive tracer Substances 0.000 description 7
238000003756 stirring Methods 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
150000003626 triacylglycerols Chemical class 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
229940100389 Sulfonylurea Drugs 0.000 description 6
108010069201 VLDL Cholesterol Proteins 0.000 description 6
239000000443 aerosol Substances 0.000 description 6
150000003863 ammonium salts Chemical class 0.000 description 6
210000004204 blood vessel Anatomy 0.000 description 6
NDGAORNQTOHHSU-UHFFFAOYSA-N ethyl 1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxylate Chemical compound C1CCC2=C1NN=C2C(=O)OCC NDGAORNQTOHHSU-UHFFFAOYSA-N 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
230000004130 lipolysis Effects 0.000 description 6
238000005259 measurement Methods 0.000 description 6
208000010125 myocardial infarction Diseases 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
239000000018 receptor agonist Substances 0.000 description 6
229940044601 receptor agonist Drugs 0.000 description 6
238000012216 screening Methods 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 5
102000030621 adenylate cyclase Human genes 0.000 description 5
108060000200 adenylate cyclase Proteins 0.000 description 5
238000010171 animal model Methods 0.000 description 5
230000003143 atherosclerotic effect Effects 0.000 description 5
239000002270 dispersing agent Substances 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
239000013613 expression plasmid Substances 0.000 description 5
230000004927 fusion Effects 0.000 description 5
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
150000005830 nonesterified fatty acids Chemical class 0.000 description 5
230000009871 nonspecific binding Effects 0.000 description 5
230000037361 pathway Effects 0.000 description 5
229920003023 plastic Polymers 0.000 description 5
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 5
230000002265 prevention Effects 0.000 description 5
230000008569 process Effects 0.000 description 5
239000007921 spray Substances 0.000 description 5
239000000375 suspending agent Substances 0.000 description 5
239000011534 wash buffer Substances 0.000 description 5
OEYYFSWAMQIPCS-UHFFFAOYSA-N 1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonitrile Chemical compound C1CCC2=C1NN=C2C#N OEYYFSWAMQIPCS-UHFFFAOYSA-N 0.000 description 4
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
238000009010 Bradford assay Methods 0.000 description 4
101150041968 CDC13 gene Proteins 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
241000282412 Homo Species 0.000 description 4
102000004877 Insulin Human genes 0.000 description 4
108090001061 Insulin Proteins 0.000 description 4
102000004895 Lipoproteins Human genes 0.000 description 4
108090001030 Lipoproteins Proteins 0.000 description 4
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 4
208000006011 Stroke Diseases 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
229960001138 acetylsalicylic acid Drugs 0.000 description 4
210000001789 adipocyte Anatomy 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
230000037396 body weight Effects 0.000 description 4
239000011575 calcium Substances 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
239000000969 carrier Substances 0.000 description 4
210000000170 cell membrane Anatomy 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
208000029078 coronary artery disease Diseases 0.000 description 4
BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
238000001914 filtration Methods 0.000 description 4
235000019253 formic acid Nutrition 0.000 description 4
230000006870 function Effects 0.000 description 4
239000000499 gel Substances 0.000 description 4
238000000265 homogenisation Methods 0.000 description 4
239000012729 immediate-release (IR) formulation Substances 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
230000000977 initiatory effect Effects 0.000 description 4
229960000367 inositol Drugs 0.000 description 4
229940125396 insulin Drugs 0.000 description 4
230000003902 lesion Effects 0.000 description 4
OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
208000031225 myocardial ischemia Diseases 0.000 description 4
238000005457 optimization Methods 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
238000013310 pig model Methods 0.000 description 4
239000004033 plastic Substances 0.000 description 4
239000004017 serum-free culture medium Substances 0.000 description 4
230000019491 signal transduction Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
239000002562 thickening agent Substances 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
238000012546 transfer Methods 0.000 description 4
239000003039 volatile agent Substances 0.000 description 4
KFHZOBHZSHIOBJ-UHFFFAOYSA-N 2-benzyl-5,6-dihydro-4h-cyclopenta[c]pyrazole-3-carboxamide Chemical compound NC(=O)C1=C2CCCC2=NN1CC1=CC=CC=C1 KFHZOBHZSHIOBJ-UHFFFAOYSA-N 0.000 description 3
108010076365 Adiponectin Proteins 0.000 description 3
206010003210 Arteriosclerosis Diseases 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
206010019280 Heart failures Diseases 0.000 description 3
101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 description 3
208000035150 Hypercholesterolemia Diseases 0.000 description 3
208000031226 Hyperlipidaemia Diseases 0.000 description 3
108060001084 Luciferase Proteins 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
150000001204 N-oxides Chemical class 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
241000282898 Sus scrofa Species 0.000 description 3
102100029337 Thyrotropin receptor Human genes 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
102000014384 Type C Phospholipases Human genes 0.000 description 3
108010079194 Type C Phospholipases Proteins 0.000 description 3
MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
230000008901 benefit Effects 0.000 description 3
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
150000004283 biguanides Chemical class 0.000 description 3
229960000074 biopharmaceutical Drugs 0.000 description 3
239000012267 brine Substances 0.000 description 3
229910002092 carbon dioxide Inorganic materials 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000003086 colorant Substances 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
229940125782 compound 2 Drugs 0.000 description 3
239000006071 cream Substances 0.000 description 3
PZAYJNNTMOGLPX-UHFFFAOYSA-N cyclopenta[c]pyrazole Chemical compound N1=NC2=CC=CC2=C1 PZAYJNNTMOGLPX-UHFFFAOYSA-N 0.000 description 3
238000013461 design Methods 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
238000010494 dissociation reaction Methods 0.000 description 3
230000005593 dissociations Effects 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
229940014259 gelatin Drugs 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000008103 glucose Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
150000002367 halogens Chemical class 0.000 description 3
230000036541 health Effects 0.000 description 3
208000019622 heart disease Diseases 0.000 description 3
231100000304 hepatotoxicity Toxicity 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
229940125425 inverse agonist Drugs 0.000 description 3
239000010410 layer Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000007056 liver toxicity Effects 0.000 description 3
239000006210 lotion Substances 0.000 description 3
239000007937 lozenge Substances 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
238000002156 mixing Methods 0.000 description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
239000002674 ointment Substances 0.000 description 3
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 3
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
230000028327 secretion Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000000829 suppository Substances 0.000 description 3
125000003831 tetrazolyl group Chemical group 0.000 description 3
150000001467 thiazolidinediones Chemical class 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
ZJSUDHQFSBHLDV-UHFFFAOYSA-N 1-[(3-bromo-1-benzofuran-2-yl)sulfonyl]imidazolidine-2,4-dione Chemical compound O1C2=CC=CC=C2C(Br)=C1S(=O)(=O)N1CC(=O)NC1=O ZJSUDHQFSBHLDV-UHFFFAOYSA-N 0.000 description 2
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
QCCHBHSAIQIQGO-UHFFFAOYSA-N 2,7-difluorospiro[fluorene-9,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2C2=CC=C(F)C=C2C21NC(=O)NC2=O QCCHBHSAIQIQGO-UHFFFAOYSA-N 0.000 description 2
QOHLJLATCLLXAB-UHFFFAOYSA-N 2-benzyl-3,4,5,6-tetrahydro-1h-cyclopenta[c]pyrazole-3-carboxamide Chemical compound N1C(CCC2)=C2C(C(=O)N)N1CC1=CC=CC=C1 QOHLJLATCLLXAB-UHFFFAOYSA-N 0.000 description 2
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
241000220479 Acacia Species 0.000 description 2
102000011690 Adiponectin Human genes 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
206010002329 Aneurysm Diseases 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
206010007559 Cardiac failure congestive Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010070901 Diabetic dyslipidaemia Diseases 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
208000032928 Dyslipidaemia Diseases 0.000 description 2
208000005171 Dysmenorrhea Diseases 0.000 description 2
206010013935 Dysmenorrhoea Diseases 0.000 description 2
201000001376 Familial Combined Hyperlipidemia Diseases 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
IHCCAYCGZOLTEU-UHFFFAOYSA-N Furane-3-carboxylic acid Natural products OC(=O)C=1C=COC=1 IHCCAYCGZOLTEU-UHFFFAOYSA-N 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
201000010252 Hyperlipoproteinemia Type III Diseases 0.000 description 2
108010001831 LDL receptors Proteins 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
208000017170 Lipid metabolism disease Diseases 0.000 description 2
108010013563 Lipoprotein Lipase Proteins 0.000 description 2
102100022119 Lipoprotein lipase Human genes 0.000 description 2
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
239000005089 Luciferase Substances 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
125000000815 N-oxide group Chemical group 0.000 description 2
239000007832 Na2SO4 Substances 0.000 description 2
MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
102000004316 Oxidoreductases Human genes 0.000 description 2
108090000854 Oxidoreductases Proteins 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
208000003251 Pruritus Diseases 0.000 description 2
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
241000282887 Suidae Species 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
206010060751 Type III hyperlipidaemia Diseases 0.000 description 2
FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
125000004423 acyloxy group Chemical group 0.000 description 2
125000004414 alkyl thio group Chemical group 0.000 description 2
BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 2
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
210000000702 aorta abdominal Anatomy 0.000 description 2
210000002376 aorta thoracic Anatomy 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
239000012911 assay medium Substances 0.000 description 2
230000008512 biological response Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
239000011111 cardboard Substances 0.000 description 2
238000000423 cell based assay Methods 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
229940125773 compound 10 Drugs 0.000 description 2
229940126214 compound 3 Drugs 0.000 description 2
229940125898 compound 5 Drugs 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 2
UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 2
230000034994 death Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
150000001982 diacylglycerols Chemical class 0.000 description 2
125000004663 dialkyl amino group Chemical group 0.000 description 2
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
229960001342 dinoprost Drugs 0.000 description 2
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000013213 extrapolation Methods 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
229960004580 glibenclamide Drugs 0.000 description 2
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
208000020887 hyperlipoproteinemia type 3 Diseases 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
238000002513 implantation Methods 0.000 description 2
239000012535 impurity Substances 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
238000001802 infusion Methods 0.000 description 2
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000007803 itching Effects 0.000 description 2
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
238000011068 loading method Methods 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
229960003365 mitiglinide Drugs 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
210000003928 nasal cavity Anatomy 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
150000002825 nitriles Chemical class 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
125000006574 non-aromatic ring group Chemical group 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
230000007505 plaque formation Effects 0.000 description 2
229920009537 polybutylene succinate adipate Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000015320 potassium carbonate Nutrition 0.000 description 2
238000002953 preparative HPLC Methods 0.000 description 2
238000003825 pressing Methods 0.000 description 2
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
239000003380 propellant Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
238000000746 purification Methods 0.000 description 2
150000003217 pyrazoles Chemical class 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
IMRLNFKFNFLWQF-IYKITFJXSA-N sorbinicate Chemical compound O([C@H](COC(=O)C=1C=NC=CC=1)[C@@H](OC(=O)C=1C=NC=CC=1)[C@H](OC(=O)C=1C=NC=CC=1)[C@H](COC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 IMRLNFKFNFLWQF-IYKITFJXSA-N 0.000 description 2
241000894007 species Species 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000003536 tetrazoles Chemical class 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000008719 thickening Effects 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
238000003146 transient transfection Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
SAZCJILIODBIBQ-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl) 5-methylpyrazine-2-carboxylate Chemical compound CCOC(=O)COC(=O)C1=CN=C(C)C=N1 SAZCJILIODBIBQ-UHFFFAOYSA-N 0.000 description 1
OELFLUMRDSZNSF-OFLPRAFFSA-N (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid Chemical compound C1CC(C(C)C)CCC1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-OFLPRAFFSA-N 0.000 description 1
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
WAAPEIZFCHNLKK-UFBFGSQYSA-N (2s,4s)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide Chemical compound C([C@H](OC1=CC=C(F)C=C11)C(=O)N)[C@@]21NC(=O)NC2=O WAAPEIZFCHNLKK-UFBFGSQYSA-N 0.000 description 1
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
JXUFSLCIJAIOJR-UHFFFAOYSA-N (5-methylpyrazin-2-yl)-morpholin-4-ylmethanone Chemical compound C1=NC(C)=CN=C1C(=O)N1CCOCC1 JXUFSLCIJAIOJR-UHFFFAOYSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
DAOMEFKPZUERHS-UHFFFAOYSA-N 1,2,3,3a-tetrahydrocyclopenta[c]pyrazole Chemical compound C1=CC2CNNC2=C1 DAOMEFKPZUERHS-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
VJGDEBQIOLVRKF-UHFFFAOYSA-N 1,4-dihydrocyclopenta[c]pyrazole-3-carbonitrile Chemical compound C1=CCC2=C(C#N)NN=C21 VJGDEBQIOLVRKF-UHFFFAOYSA-N 0.000 description 1
NLVOZISXXFOEIU-UHFFFAOYSA-N 1,4-dihydrocyclopenta[c]pyrazole-3-carboxamide Chemical compound C1=CCC2=C1NN=C2C(=O)N NLVOZISXXFOEIU-UHFFFAOYSA-N 0.000 description 1
IAOXGQOZAHLHAS-UHFFFAOYSA-N 1,6-dihydrocyclopenta[c]pyrazole-3-carbonitrile Chemical compound C1C=CC2=C(C#N)NN=C21 IAOXGQOZAHLHAS-UHFFFAOYSA-N 0.000 description 1
LAERHRRVIVXBED-UHFFFAOYSA-N 1,6-dihydrocyclopenta[c]pyrazole-3-carboxamide Chemical compound C1C=CC2=C(C(=O)N)NN=C21 LAERHRRVIVXBED-UHFFFAOYSA-N 0.000 description 1
ARSTYWCBFCDLSO-UHFFFAOYSA-N 1-(3-aminophenyl)sulfonyl-3-butylurea Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=CC(N)=C1 ARSTYWCBFCDLSO-UHFFFAOYSA-N 0.000 description 1
BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
PMGZJNCIQHGNLT-UHFFFAOYSA-N 1-[bis(2,2-dimethylpropanoyloxymethoxy)phosphoryl]-4-(3-phenoxyphenyl)butane-1-sulfonic acid Chemical compound CC(C)(C)C(=O)OCOP(=O)(OCOC(=O)C(C)(C)C)C(S(O)(=O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 PMGZJNCIQHGNLT-UHFFFAOYSA-N 0.000 description 1
LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
KOPFEFZSAMLEHK-UHFFFAOYSA-N 1h-pyrazole-5-carboxylic acid Chemical class OC(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-N 0.000 description 1
ANZPCVLDIYQKTB-UHFFFAOYSA-N 1h-thieno[3,4-c]pyrazole Chemical compound S1C=C2C=NNC2=C1 ANZPCVLDIYQKTB-UHFFFAOYSA-N 0.000 description 1
239000003315 2-(4-chlorophenoxy)-2-methylpropanoic acid Substances 0.000 description 1
UEYQJQVBUVAELZ-UHFFFAOYSA-N 2-Hydroxynicotinic acid Chemical compound OC(=O)C1=CC=CN=C1O UEYQJQVBUVAELZ-UHFFFAOYSA-N 0.000 description 1
CLDJCRWXLDLJLO-UHFFFAOYSA-N 2-[2,8-di(propan-2-yl)-3-sulfanylidene-1,4-benzoxazin-4-yl]acetic acid Chemical compound C1=CC=C2N(CC(O)=O)C(=S)C(C(C)C)OC2=C1C(C)C CLDJCRWXLDLJLO-UHFFFAOYSA-N 0.000 description 1
NOGMJZHLDVYCSP-UHFFFAOYSA-N 2-hydroxyethyl 5-methylpyrazine-2-carboxylate Chemical compound CC1=CN=C(C(=O)OCCO)C=N1 NOGMJZHLDVYCSP-UHFFFAOYSA-N 0.000 description 1
CKRDSNDHOKHGBP-UHFFFAOYSA-N 2-methyl-5-(2h-tetrazol-5-yl)pyrazine Chemical compound C1=NC(C)=CN=C1C1=NN=NN1 CKRDSNDHOKHGBP-UHFFFAOYSA-N 0.000 description 1
FJZRUSFQHBBTCC-UHFFFAOYSA-N 2-oxo-1h-pyrazine-3-carboxylic acid Chemical compound OC(=O)C1=NC=CNC1=O FJZRUSFQHBBTCC-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
BCSVCWVQNOXFGL-UHFFFAOYSA-N 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(C(F)(F)F)=CC=C2S1 BCSVCWVQNOXFGL-UHFFFAOYSA-N 0.000 description 1
NCTWQUYOOHAZLQ-UHFFFAOYSA-N 3-(2h-tetrazol-5-yl)quinoline Chemical compound C=1C2=CC=CC=C2N=CC=1C1=NN=NN1 NCTWQUYOOHAZLQ-UHFFFAOYSA-N 0.000 description 1
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
YHPMRHPLAQSPHJ-UHFFFAOYSA-N 3-chloropyrazine-2-carboxamide Chemical compound NC(=O)C1=NC=CN=C1Cl YHPMRHPLAQSPHJ-UHFFFAOYSA-N 0.000 description 1
LZYQFKPLSBGGTK-UHFFFAOYSA-N 3-methoxypyrazine-2-carboxamide Chemical compound COC1=NC=CN=C1C(N)=O LZYQFKPLSBGGTK-UHFFFAOYSA-N 0.000 description 1
HXIYCKAAQPHZBM-UHFFFAOYSA-N 3-methyl-1,2-oxazole-5-carboxylic acid Chemical compound CC=1C=C(C(O)=O)ON=1 HXIYCKAAQPHZBM-UHFFFAOYSA-N 0.000 description 1
GMJGOIWOVGUYSD-UHFFFAOYSA-N 3-methyl-5-(2h-tetrazol-5-yl)-1,2-oxazole Chemical compound O1N=C(C)C=C1C1=NN=NN1 GMJGOIWOVGUYSD-UHFFFAOYSA-N 0.000 description 1
125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
WGNUNYPERJMVRM-UHFFFAOYSA-N 3-pyridylacetic acid Chemical compound OC(=O)CC1=CC=CN=C1 WGNUNYPERJMVRM-UHFFFAOYSA-N 0.000 description 1
NMSNDQYLVCJWOY-UHFFFAOYSA-N 4-(2h-tetrazol-5-yl)benzene-1,2-diamine Chemical compound C1=C(N)C(N)=CC=C1C1=NNN=N1 NMSNDQYLVCJWOY-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
AMGHNLUOZWKJHV-UHFFFAOYSA-N 4h-furo[3,4-c]pyrazole Chemical compound N1=NC=C2COC=C21 AMGHNLUOZWKJHV-UHFFFAOYSA-N 0.000 description 1
JAVGJSUOZDZWBY-UHFFFAOYSA-N 5-aminopyrazine-2-carboxamide Chemical compound NC(=O)C1=CN=C(N)C=N1 JAVGJSUOZDZWBY-UHFFFAOYSA-N 0.000 description 1
FMEFOOOBIHQRMK-UHFFFAOYSA-N 5-aminopyrazine-2-carboxylic acid Chemical compound NC1=CN=C(C(O)=O)C=N1 FMEFOOOBIHQRMK-UHFFFAOYSA-N 0.000 description 1
RKKVEAAVLJJAKZ-UHFFFAOYSA-N 5-benzylpyrazine-2-carboxamide Chemical compound C1=NC(C(=O)N)=CN=C1CC1=CC=CC=C1 RKKVEAAVLJJAKZ-UHFFFAOYSA-N 0.000 description 1
MUJKERBACNEKFE-UHFFFAOYSA-N 5-benzylpyrazine-2-carboxylic acid Chemical compound C1=NC(C(=O)O)=CN=C1CC1=CC=CC=C1 MUJKERBACNEKFE-UHFFFAOYSA-N 0.000 description 1
GFEFMHWOSWUJSO-UHFFFAOYSA-N 5-chloropyrazine-2-carboxamide Chemical compound NC(=O)C1=CN=C(Cl)C=N1 GFEFMHWOSWUJSO-UHFFFAOYSA-N 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
WAUSRINIZKXDNU-UHFFFAOYSA-N 5-methyl-3-(2h-tetrazol-5-yl)-1,2-oxazole Chemical compound O1C(C)=CC(C=2NN=NN=2)=N1 WAUSRINIZKXDNU-UHFFFAOYSA-N 0.000 description 1
FIPNNYCYRCSORF-UHFFFAOYSA-N 5-methyl-n-(3-methylpyrazin-2-yl)pyrazine-2-carboxamide Chemical compound C1=NC(C)=CN=C1C(=O)NC1=NC=CN=C1C FIPNNYCYRCSORF-UHFFFAOYSA-N 0.000 description 1
XJIMQRSHPUNVII-UHFFFAOYSA-N 5-methyl-n-(5-methylpyrazin-2-yl)pyrazine-2-carboxamide Chemical compound C1=NC(C)=CN=C1NC(=O)C1=CN=C(C)C=N1 XJIMQRSHPUNVII-UHFFFAOYSA-N 0.000 description 1
IZMNTLXDCMNKAP-UHFFFAOYSA-N 5-methyl-n-(6-methylpyrazin-2-yl)pyrazine-2-carboxamide Chemical compound C1=NC(C)=CN=C1C(=O)NC1=CN=CC(C)=N1 IZMNTLXDCMNKAP-UHFFFAOYSA-N 0.000 description 1
RBYJWCRKFLGNDB-UHFFFAOYSA-N 5-methylpyrazine-2-carboxylic acid Chemical compound CC1=CN=C(C(O)=O)C=N1 RBYJWCRKFLGNDB-UHFFFAOYSA-N 0.000 description 1
DJDHHXDFKSLEQY-UHFFFAOYSA-N 5-methylpyridine-3-carboxylic acid Chemical compound CC1=CN=CC(C(O)=O)=C1 DJDHHXDFKSLEQY-UHFFFAOYSA-N 0.000 description 1
JEERXOCCQAMKAF-UHFFFAOYSA-N 6-chloropyrazine-2-carboxamide Chemical compound NC(=O)C1=CN=CC(Cl)=N1 JEERXOCCQAMKAF-UHFFFAOYSA-N 0.000 description 1
KGGYMBKTQCLOTE-UHFFFAOYSA-N 6-chloropyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC(Cl)=N1 KGGYMBKTQCLOTE-UHFFFAOYSA-N 0.000 description 1
WAAPEIZFCHNLKK-UHFFFAOYSA-N 6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide Chemical compound C12=CC(F)=CC=C2OC(C(=O)N)CC21NC(=O)NC2=O WAAPEIZFCHNLKK-UHFFFAOYSA-N 0.000 description 1
UUXPHCXTKJQYKP-UHFFFAOYSA-N 6-methoxypyrazine-2-carboxamide Chemical compound COC1=CN=CC(C(N)=O)=N1 UUXPHCXTKJQYKP-UHFFFAOYSA-N 0.000 description 1
RWGSCFHUIFPLEI-UHFFFAOYSA-N 6-methoxypyrazine-2-carboxylic acid Chemical compound COC1=CN=CC(C(O)=O)=N1 RWGSCFHUIFPLEI-UHFFFAOYSA-N 0.000 description 1
RZOKQIPOABEQAM-UHFFFAOYSA-N 6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC=C(C(O)=O)C=N1 RZOKQIPOABEQAM-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical group CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
102100029470 Apolipoprotein E Human genes 0.000 description 1
101710095339 Apolipoprotein E Proteins 0.000 description 1
108010060219 Apolipoprotein E2 Proteins 0.000 description 1
108010060215 Apolipoprotein E3 Proteins 0.000 description 1
102000008128 Apolipoprotein E3 Human genes 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101150043532 CISH gene Proteins 0.000 description 1
101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 description 1
RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
102000004420 Creatine Kinase Human genes 0.000 description 1
108010042126 Creatine kinase Proteins 0.000 description 1
101710095468 Cyclase Proteins 0.000 description 1
102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
108010066671 Enalaprilat Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
206010016334 Feeling hot Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102100030279 G-protein coupled receptor 35 Human genes 0.000 description 1
102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
108091006109 GTPases Proteins 0.000 description 1
101000887162 Gallus gallus Gallinacin-5 Proteins 0.000 description 1
101000887166 Gallus gallus Gallinacin-7 Proteins 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
108091006101 Gi proteins Proteins 0.000 description 1
102000034354 Gi proteins Human genes 0.000 description 1
108091006065 Gs proteins Proteins 0.000 description 1
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
101001009545 Homo sapiens G-protein coupled receptor 35 Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 description 1
101710125793 Hydroxycarboxylic acid receptor 2 Proteins 0.000 description 1
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
108010046315 IDL Lipoproteins Proteins 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
PMRVFZXOCRHXFE-FMEJWYFOSA-L Kad 1229 Chemical compound [Ca+2].C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1.C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1 PMRVFZXOCRHXFE-FMEJWYFOSA-L 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
238000012773 Laboratory assay Methods 0.000 description 1
108010007859 Lisinopril Proteins 0.000 description 1
IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
MQSLJSUNUUVDOI-UHFFFAOYSA-N N-hydroxy-5-methylpyrazine-2-carboxamide Chemical compound CC1=CN=C(C(=O)NO)C=N1 MQSLJSUNUUVDOI-UHFFFAOYSA-N 0.000 description 1
KTLRWTOPTKGYQY-UHFFFAOYSA-N N-methyl-4-pyridone-3-carboxamide Chemical compound CN1C=CC(=O)C(C(N)=O)=C1 KTLRWTOPTKGYQY-UHFFFAOYSA-N 0.000 description 1
ZYVXHFWBYUDDBM-UHFFFAOYSA-N N-methylnicotinamide Chemical compound CNC(=O)C1=CC=CN=C1 ZYVXHFWBYUDDBM-UHFFFAOYSA-N 0.000 description 1
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
KUEUWHJGRZKESU-UHFFFAOYSA-N Niceritrol Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 KUEUWHJGRZKESU-UHFFFAOYSA-N 0.000 description 1
USSFUVKEHXDAPM-UHFFFAOYSA-N Nicotinamide N-oxide Chemical compound NC(=O)C1=CC=C[N+]([O-])=C1 USSFUVKEHXDAPM-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
241000288906 Primates Species 0.000 description 1
101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
101000608768 Rattus norvegicus Galectin-5 Proteins 0.000 description 1
101100015376 Rattus norvegicus Gnaz gene Proteins 0.000 description 1
101000633010 Rattus norvegicus Somatostatin Proteins 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
108091006629 SLC13A2 Proteins 0.000 description 1
101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 1
102000000019 Sterol Esterase Human genes 0.000 description 1
108010055297 Sterol Esterase Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
102400000472 Sucrase Human genes 0.000 description 1
101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
229930003537 Vitamin B3 Natural products 0.000 description 1
108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
229960002632 acarbose Drugs 0.000 description 1
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
229960001466 acetohexamide Drugs 0.000 description 1
VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229950007884 alacepril Drugs 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
229960005142 alclofenac Drugs 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000005332 alkyl sulfoxy group Chemical group 0.000 description 1
102000016679 alpha-Glucosidases Human genes 0.000 description 1
108010028144 alpha-Glucosidases Proteins 0.000 description 1
NSFYKDVWNTWJOK-UHFFFAOYSA-K aluminum;pyridine-3-carboxylate Chemical compound [Al+3].[O-]C(=O)C1=CC=CN=C1.[O-]C(=O)C1=CC=CN=C1.[O-]C(=O)C1=CC=CN=C1 NSFYKDVWNTWJOK-UHFFFAOYSA-K 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000006538 anaerobic glycolysis Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
230000000489 anti-atherogenic effect Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
238000010936 aqueous wash Methods 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229960005370 atorvastatin Drugs 0.000 description 1
238000002869 basic local alignment search tool Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
229950009252 beclobrate Drugs 0.000 description 1
YWQGBCXVCXMSLJ-UHFFFAOYSA-N beclobrate Chemical compound C1=CC(OC(C)(CC)C(=O)OCC)=CC=C1CC1=CC=C(Cl)C=C1 YWQGBCXVCXMSLJ-UHFFFAOYSA-N 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
230000006399 behavior Effects 0.000 description 1
229960004530 benazepril Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229960005430 benoxaprofen Drugs 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
229960000516 bezafibrate Drugs 0.000 description 1
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229950004495 binifibrate Drugs 0.000 description 1
BFYRHDVAEJIBON-UHFFFAOYSA-N binifibrate Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 BFYRHDVAEJIBON-UHFFFAOYSA-N 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
239000012455 biphasic mixture Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229960004111 buformin Drugs 0.000 description 1
XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000013262 cAMP assay Methods 0.000 description 1
230000003491 cAMP production Effects 0.000 description 1
QEVLNUAVAONTEW-UZYHXJQGSA-L calcium;(2s)-4-[(3as,7ar)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoate;dihydrate Chemical compound O.O.[Ca+2].C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1.C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1 QEVLNUAVAONTEW-UZYHXJQGSA-L 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
229960003362 carbutamide Drugs 0.000 description 1
VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
229960003184 carprofen Drugs 0.000 description 1
IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
229960000590 celecoxib Drugs 0.000 description 1
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
229960005110 cerivastatin Drugs 0.000 description 1
229950005749 ceronapril Drugs 0.000 description 1
BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 1
229960001761 chlorpropamide Drugs 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
229960005025 cilazapril Drugs 0.000 description 1
HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
230000004087 circulation Effects 0.000 description 1
229950003072 clinofibrate Drugs 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
229950008441 clofibric acid Drugs 0.000 description 1
TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 1
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000000306 component Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000006552 constitutive activation Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
239000013058 crude material Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
229960005227 delapril Drugs 0.000 description 1
WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
102000038379 digestive enzymes Human genes 0.000 description 1
108091007734 digestive enzymes Proteins 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000003028 elevating effect Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960002680 enalaprilat Drugs 0.000 description 1
LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
229950010170 epalrestat Drugs 0.000 description 1
CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
ARCQSBHQBYKAER-UHFFFAOYSA-N ethyl 1,4-dihydrocyclopenta[c]pyrazole-3-carboxylate Chemical compound C1=CCC2=C(C(=O)OCC)NN=C21 ARCQSBHQBYKAER-UHFFFAOYSA-N 0.000 description 1
YPKUAMRKKFDJCN-UHFFFAOYSA-N ethyl 1,6-dihydrocyclopenta[c]pyrazole-3-carboxylate Chemical compound C1C=CC2=C(C(=O)OCC)NN=C21 YPKUAMRKKFDJCN-UHFFFAOYSA-N 0.000 description 1
229960005293 etodolac Drugs 0.000 description 1
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
229960003501 etofibrate Drugs 0.000 description 1
XXRVYAFBUDSLJX-UHFFFAOYSA-N etofibrate Chemical compound C=1C=CN=CC=1C(=O)OCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 XXRVYAFBUDSLJX-UHFFFAOYSA-N 0.000 description 1
229950009036 etofylline clofibrate Drugs 0.000 description 1
KYAKGJDISSNVPZ-UHFFFAOYSA-N etofylline clofibrate Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KYAKGJDISSNVPZ-UHFFFAOYSA-N 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 1
229950006236 fenclofenac Drugs 0.000 description 1
229960002297 fenofibrate Drugs 0.000 description 1
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
229960001419 fenoprofen Drugs 0.000 description 1
229960002390 flurbiprofen Drugs 0.000 description 1
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
229960003765 fluvastatin Drugs 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
229960002490 fosinopril Drugs 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
208000015707 frontal fibrosing alopecia Diseases 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
229960003627 gemfibrozil Drugs 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960000346 gliclazide Drugs 0.000 description 1
229960004346 glimepiride Drugs 0.000 description 1
WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
229960001381 glipizide Drugs 0.000 description 1
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
229960003468 gliquidone Drugs 0.000 description 1
229960003236 glisoxepide Drugs 0.000 description 1
ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 description 1
230000004110 gluconeogenesis Effects 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
DVQVBLBKEXITIK-UHFFFAOYSA-N glybuthiazol Chemical compound S1C(C(C)(C)C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 DVQVBLBKEXITIK-UHFFFAOYSA-N 0.000 description 1
229950011569 glybuthiazol Drugs 0.000 description 1
229950005514 glycyclamide Drugs 0.000 description 1
RIGBPMDIGYBTBJ-UHFFFAOYSA-N glycyclamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 RIGBPMDIGYBTBJ-UHFFFAOYSA-N 0.000 description 1
NFRPNQDSKJJQGV-UHFFFAOYSA-N glyhexamide Chemical compound C=1C=C2CCCC2=CC=1S(=O)(=O)NC(=O)NC1CCCCC1 NFRPNQDSKJJQGV-UHFFFAOYSA-N 0.000 description 1
229950008290 glyhexamide Drugs 0.000 description 1
QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
229960004440 glymidine Drugs 0.000 description 1
RHQSNARBXHRBNP-UHFFFAOYSA-N glypinamide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 RHQSNARBXHRBNP-UHFFFAOYSA-N 0.000 description 1
229950009188 glypinamide Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
229950007593 homonicotinic acid Drugs 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
229960001195 imidapril Drugs 0.000 description 1
KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
229950007327 imirestat Drugs 0.000 description 1
239000012727 immediate-release (IR) form Substances 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
235000011073 invertase Nutrition 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
229940039009 isoproterenol Drugs 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
229960005417 ketanserin Drugs 0.000 description 1
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
229960000991 ketoprofen Drugs 0.000 description 1
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
229960004752 ketorolac Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
229960002394 lisinopril Drugs 0.000 description 1
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229940013798 meclofenamate Drugs 0.000 description 1
SBDNJUWAMKYJOX-UHFFFAOYSA-M meclofenamic acid(1-) Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-M 0.000 description 1
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
210000003574 melanophore Anatomy 0.000 description 1
210000004914 menses Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
229960003105 metformin Drugs 0.000 description 1
TWIIRMSFZNYMQE-UHFFFAOYSA-N methyl pyrazine-2-carboxylate Chemical compound COC(=O)C1=CN=CC=N1 TWIIRMSFZNYMQE-UHFFFAOYSA-N 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
229960001110 miglitol Drugs 0.000 description 1
WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
JJNNWWOHMWHRAB-UHFFFAOYSA-N n-ethylpyrazine-2-carboxamide Chemical compound CCNC(=O)C1=CN=CC=N1 JJNNWWOHMWHRAB-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960004270 nabumetone Drugs 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
229960000698 nateglinide Drugs 0.000 description 1
235000021096 natural sweeteners Nutrition 0.000 description 1
239000013642 negative control Substances 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229960000827 niceritrol Drugs 0.000 description 1
229950005171 nicofibrate Drugs 0.000 description 1
RARQHAFNGNPQCZ-UHFFFAOYSA-N nicofibrate Chemical compound C=1C=CN=CC=1COC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 RARQHAFNGNPQCZ-UHFFFAOYSA-N 0.000 description 1
DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
NPORIZAYKBQYLF-LREBCSMRSA-N nicotinyl alcohol tartrate Chemical compound OCC1=CC=CN=C1.OC(=O)[C@H](O)[C@@H](O)C(O)=O NPORIZAYKBQYLF-LREBCSMRSA-N 0.000 description 1
229960000839 nicotinyl alcohol tartrate Drugs 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000004305 normal phase HPLC Methods 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
201000005111 ocular hyperemia Diseases 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
108091008880 orphan GPCRs Proteins 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
229960002739 oxaprozin Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
FJCFFCXMEXZEIM-UHFFFAOYSA-N oxiniacic acid Chemical compound OC(=O)C1=CC=C[N+]([O-])=C1 FJCFFCXMEXZEIM-UHFFFAOYSA-N 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
229960000649 oxyphenbutazone Drugs 0.000 description 1
HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
238000012858 packaging process Methods 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000000123 paper Substances 0.000 description 1
239000011087 paperboard Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
229960001779 pargyline Drugs 0.000 description 1
239000006072 paste Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
229960002582 perindopril Drugs 0.000 description 1
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
238000005502 peroxidation Methods 0.000 description 1
239000003614 peroxisome proliferator Substances 0.000 description 1
AFOGBLYPWJJVAL-UHFFFAOYSA-N phenbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=CC=C1 AFOGBLYPWJJVAL-UHFFFAOYSA-N 0.000 description 1
229950008557 phenbutamide Drugs 0.000 description 1
229960003243 phenformin Drugs 0.000 description 1
ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
229960003531 phenolsulfonphthalein Drugs 0.000 description 1
ODPJKMXQKNJXGS-UHFFFAOYSA-N phenyl 5-methylpyrazine-2-carboxylate Chemical compound C1=NC(C)=CN=C1C(=O)OC1=CC=CC=C1 ODPJKMXQKNJXGS-UHFFFAOYSA-N 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
229960005095 pioglitazone Drugs 0.000 description 1
229950000957 pirifibrate Drugs 0.000 description 1
YJBIJSVYPHRVCI-UHFFFAOYSA-N pirifibrate Chemical compound C=1C=CC(CO)=NC=1COC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 YJBIJSVYPHRVCI-UHFFFAOYSA-N 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229960002965 pravastatin Drugs 0.000 description 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
150000003163 prostaglandin D2 derivatives Chemical class 0.000 description 1
230000012743 protein tagging Effects 0.000 description 1
NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 1
IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
JUSIWJONLKBPDU-UHFFFAOYSA-N pyridazine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NN=C1 JUSIWJONLKBPDU-UHFFFAOYSA-N 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
238000010791 quenching Methods 0.000 description 1
229960001455 quinapril Drugs 0.000 description 1
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
229960003401 ramipril Drugs 0.000 description 1
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
238000003571 reporter gene assay Methods 0.000 description 1
230000033458 reproduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000006965 reversible inhibition Effects 0.000 description 1
238000012502 risk assessment Methods 0.000 description 1
229960000371 rofecoxib Drugs 0.000 description 1
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
229960000804 ronifibrate Drugs 0.000 description 1
AYJVGKWCGIYEAK-UHFFFAOYSA-N ronifibrate Chemical compound C=1C=CN=CC=1C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 AYJVGKWCGIYEAK-UHFFFAOYSA-N 0.000 description 1
229960004586 rosiglitazone Drugs 0.000 description 1
229960000672 rosuvastatin Drugs 0.000 description 1
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
102200074665 rs121908860 Human genes 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
239000000523 sample Substances 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
229960004058 simfibrate Drugs 0.000 description 1
229960002855 simvastatin Drugs 0.000 description 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
239000002356 single layer Substances 0.000 description 1
230000004037 social stress Effects 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
229950007581 sorbinicate Drugs 0.000 description 1
LXANPKRCLVQAOG-NSHDSACASA-N sorbinil Chemical compound C12=CC(F)=CC=C2OCC[C@@]21NC(=O)NC2=O LXANPKRCLVQAOG-NSHDSACASA-N 0.000 description 1
229950004311 sorbinil Drugs 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000009987 spinning Methods 0.000 description 1
229960002909 spirapril Drugs 0.000 description 1
HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
108700035424 spirapril Proteins 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229910052717 sulfur Chemical group 0.000 description 1
239000011593 sulfur Chemical group 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
229960004492 suprofen Drugs 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000003760 tallow Substances 0.000 description 1
229960004084 temocapril Drugs 0.000 description 1
FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 1
229960002277 tolazamide Drugs 0.000 description 1
OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
229960005371 tolbutamide Drugs 0.000 description 1
229960001017 tolmetin Drugs 0.000 description 1
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
239000006208 topical dosage form Substances 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
229960002051 trandolapril Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
108010002139 very low density lipoprotein triglyceride Proteins 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000019160 vitamin B3 Nutrition 0.000 description 1
239000011708 vitamin B3 Substances 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
229960001729 voglibose Drugs 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
239000003643 water by type Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
SXONDGSPUVNZLO-UHFFFAOYSA-N zenarestat Chemical compound O=C1N(CC(=O)O)C2=CC(Cl)=CC=C2C(=O)N1CC1=CC=C(Br)C=C1F SXONDGSPUVNZLO-UHFFFAOYSA-N 0.000 description 1
229950006343 zenarestat Drugs 0.000 description 1
229940102001 zinc bromide Drugs 0.000 description 1
ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1
229960003414 zomepirac Drugs 0.000 description 1
229950005346 zopolrestat Drugs 0.000 description 1